share_log

BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market

BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market

BioHarvest Sciences宣佈將上市至納斯達克全球市場
newsfile ·  11/07 21:30

Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024

普通股將於2024年11月12日星期二開始在納斯達克交易

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Nasdaq Stock Market LLC has approved the listing of the Company's common shares on the Nasdaq Global Market ("Nasdaq").

溫哥華,不列顛哥倫比亞和以色列雷霍沃特-(Newsfile 企業 - 2024年11月7日) - BioHarvest Sciences 公司(CSE: BHSC)(OTCQB: CNVCF)("BioHarvest" 或 "公司"),一家開創性的專利植物合成技術平台公司,今日宣佈,納斯達克證券交易所公司普通股的上市獲得了納斯達克全球市場("納斯達克")的批准。

The Company expects to begin trading on the Nasdaq on Tuesday, November 12th, 2024, under the new symbol "BHST". The company's common shares will trade on the OTCQB until market close on November 11th, 2024, and will continue to trade on the Canadian Securities Exchange ("CSE").

公司預計將於2024年11月12日星期二開始在納斯達克交易,新股票代號爲"BHST"。 公司的普通股將在2024年11月11日市場閉市前繼續在OTCQb上交易,並將繼續在加拿大證券交易所("CSE")交易。

Dr. Zaki Rakib, Chairman of BioHarvest Sciences, said: "We are pleased to announce the listing of our shares on the Nasdaq, representing a significant capital markets milestone for BioHarvest Sciences and our valued shareholder partners. We believe this listing will serve to expand our potential shareholder base, improve liquidity and elevate our public profile in the industry - ultimately helping to enhance long-term shareholder value creation."

BioHarvest Sciences 主席扎基·拉基布博士表示:"我們很高興宣佈我們的股票將在納斯達克上市,這標誌着BioHarvest Sciences和我們尊貴股東合作伙伴的資本市場重要里程碑。 我們相信這一上市將有助於擴大我們潛在的股東基礎,提高流動性和提升我們在行業中的公衆形象-最終有助於增加長期股東價值的創造。"

Ilan Sobel, Chief Executive Officer of BioHarvest Sciences, concluded: "I am incredibly proud of the efforts of the whole team at BioHarvest, whose operational execution has positioned us to list on a senior U.S. exchange and tap into a global shareholder base. We look forward to our first day of trading on the Nasdaq on Tuesday, November 12, 2024. I would like to thank our valued shareholder partners, whose significant support has played an important role in our continued success."

BioHarvest Sciences 首席執行官伊蘭·索貝爾總結說:"我爲BioHarvest整個團隊的努力感到非常自豪,他們的運營執行使我們有資格在美國的一家高級交易所上市,同時能夠吸引全球股東基礎。我們期待在2024年11月12日星期二在納斯達克上市的第一天。我要感謝我們尊貴的股東合作伙伴,他們的重要支持在我們持續成功中發揮了重要作用。"

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc.簡介

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .

BioHarvest Sciences 公司(CSE: BHSC)(OTCQB: CNVCF)(FSE: 8MV0)是植物合成領域的領導者,利用其專利技術平台在無需種植植物的情況下培育植物的活性成分。BioHarvest 正在利用其植物合成技術開發下一代基於科學且經臨床證實的治療解決方案,主要涉足兩個主要業務垂直領域;作爲代表尋求複雜分子的客戶的合同開發和生產組織(CDMO),以及作爲專有保健和健康產品的創新者,其中包括膳食補充劑。欲了解更多信息,請訪問。

Forward-Looking Statements

前瞻性聲明

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

本新聞稿中提供的信息可能包含基於管理層目前的估計、信念、意圖和期望的前瞻性陳述,並受到一系列風險和不確定性的影響,這些風險和不確定性可能導致實際結果與前瞻性陳述中描述的結果有實質性差異。未來的合同並無保證。讀者應注意,未來的合同或增加的營業收入並不一定會帶來淨利潤或盈利能力的提高,因爲成本很可能也會增加。所有前瞻性陳述都存在不確定性,實際結果可能受到我們無法控制的一系列重要因素的影響。讀者不應過度依賴前瞻性陳述。BHSC不打算通過其他途徑更新前瞻性聲明披露,除非通過我們定期的管理層討論和分析披露。

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其規定服務供應商對本聲明的充分性或準確性不承擔任何責任。

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.

此新聞稿已由VP Investor Relations戴夫·瑞安審查並批准,他對其內容負責。

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
(604) 622-1186
info@bioharvest.com

BioHarvest的公司聯繫方式:
Dave Ryan,投資者關係和董事副總裁
(604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHSC@mzgroup.us

投資者關係聯繫人:
Lucas A. Zimmerman
董事總經理
MZ Group - MZ North America
(949) 259-4987
BHSC@mzgroup.us

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論